Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Invested Capital (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Return on Invested Capital for 15 consecutive years, with 0.73% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Invested Capital fell 56.0% to 0.73% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.73%, a 56.0% decrease, with the full-year FY2025 number at 0.58%, down 42.0% from a year prior.
  • Return on Invested Capital was 0.73% for Q4 2025 at Myriad Genetics, up from 0.84% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.04% in Q1 2022 to a low of 0.84% in Q3 2025.
  • A 5-year average of 0.26% and a median of 0.17% in 2023 define the central range for Return on Invested Capital.
  • Peak YoY movement for Return on Invested Capital: rose 21bps in 2024, then plummeted -69bps in 2025.
  • Myriad Genetics' Return on Invested Capital stood at 0.09% in 2021, then plummeted by -33bps to 0.12% in 2022, then crashed by -169bps to 0.33% in 2023, then skyrocketed by 50bps to 0.17% in 2024, then plummeted by -334bps to 0.73% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Return on Invested Capital are 0.73% (Q4 2025), 0.84% (Q3 2025), and 0.65% (Q2 2025).